Fewer than 40% of U.S. healthcare and life sciences operators are prepared for potential regulatory and policy changes, exposing a major vulnerability as structural cost pressures mount. Data from the inaugural AlixPartners U.S. Healthcare & Life Sciences Distress Survey shows that the industry's traditional business model is failing to balance affordability with rising operating costs. This instability is driven in part by global drug pricing pressures created by U.S. administration most-favored-nation policies.
Corporate growth strategies are stalling due to widespread execution bottlenecks across the sector. Although more than 90% of industry executives state they are prioritizing strategic M&A, a mere 27% are actually prepared to execute deals quickly. Furthermore, despite a boom in artificial intelligence implementation across healthcare operations, only one-third of operators have realized clear, measurable financial returns from the technology.
A sharp divide has opened between internal corporate realities and external market sentiment, with investors and advisors remaining far more bullish on AI and transformation tools than operators. This mismatch is forcing organizations to overhaul their corporate governance and establish realistic financial planning metrics. Randall Eisenberg, Americas Co-Leader of Healthcare and Life Sciences at AlixPartners, stated that "proactive actions be taken to secure reasonable levels of profitability."